Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

ΔNp63 activates EGFR signaling to induce loss of adhesion in triple-negative basal-like breast cancer cells

J. Holcakova, M. Nekulova, P. Orzol, R. Nenutil, J. Podhorec, M. Svoboda, P. Dvorakova, M. Pjechova, L. Hernychova, B. Vojtesek, PJ. Coates,

. 2017 ; 163 (3) : 475-484. [pub] 20170327

Jazyk angličtina Země Nizozemsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc18010719
E-zdroje Online Plný text

NLK ProQuest Central od 1997-01-01 do Před 1 rokem
Medline Complete (EBSCOhost) od 2005-01-01 do Před 1 rokem
Health & Medicine (ProQuest) od 1997-01-01 do Před 1 rokem
Family Health Database (ProQuest) od 1997-01-01 do Před 1 rokem
Public Health Database (ProQuest) od 1997-01-01 do Před 1 rokem

PURPOSE: The basal-A subtype of triple-negative breast cancer is characterized by high levels of ΔNp63. Various functions have been proposed for p63 in breast cancer initiation and growth, and p63 mediates chemotherapeutic response in a subset of triple-negative breast cancers. We investigated the signaling pathways that are controlled by ΔNp63 in basal-A triple-negative breast cancer. METHODS: Human basal-A triple-negative breast cancer cell lines with ΔNp63α induction or inhibition were studied, along with primary human triple-negative breast cancer tissues. Proteomic, phospho-kinase array, mRNA measurements, and immunohistochemistry were employed. RESULTS: Global phosphoproteomics identified increased EGFR phosphorylation in MDA-MB-468 cells expressing ΔNp63α. ΔNp63α expression increased EGFR mRNA, total EGFR protein, and phospho-EGFR(Y1086), whereas silencing endogenous ΔNp63 in HCC1806 cells reduced both total and phospho-EGFR levels and inhibited the ability of EGF to activate EGFR. EGFR pathway gene expression analysis indicated that ΔNp63 alters EGFR-regulated genes involved in cell adhesion, migration, and angiogenesis. Addition of EGF or neutralizing EGFR antibodies demonstrated that EGFR activation is responsible for ΔNp63-mediated loss of cellular adhesion. Finally, immunohistochemical staining showed that p63-positive triple-negative breast cancers were more likely to express high levels of EGFR than p63-negative cancers, corroborated by in silico analysis of gene expression profiling data. CONCLUSIONS: These data identify EGFR as a major target for ΔNp63 regulation that influences cancer cell adhesion in basal-like triple-negative breast cancer.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18010719
003      
CZ-PrNML
005      
20180419102152.0
007      
ta
008      
180404s2017 ne f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s10549-017-4216-6 $2 doi
035    __
$a (PubMed)28349272
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Holcakova, Jitka $u RECAMO, Masaryk Memorial Cancer Centre, Zluty kopec 7, 65633, Brno, Czech Republic.
245    10
$a ΔNp63 activates EGFR signaling to induce loss of adhesion in triple-negative basal-like breast cancer cells / $c J. Holcakova, M. Nekulova, P. Orzol, R. Nenutil, J. Podhorec, M. Svoboda, P. Dvorakova, M. Pjechova, L. Hernychova, B. Vojtesek, PJ. Coates,
520    9_
$a PURPOSE: The basal-A subtype of triple-negative breast cancer is characterized by high levels of ΔNp63. Various functions have been proposed for p63 in breast cancer initiation and growth, and p63 mediates chemotherapeutic response in a subset of triple-negative breast cancers. We investigated the signaling pathways that are controlled by ΔNp63 in basal-A triple-negative breast cancer. METHODS: Human basal-A triple-negative breast cancer cell lines with ΔNp63α induction or inhibition were studied, along with primary human triple-negative breast cancer tissues. Proteomic, phospho-kinase array, mRNA measurements, and immunohistochemistry were employed. RESULTS: Global phosphoproteomics identified increased EGFR phosphorylation in MDA-MB-468 cells expressing ΔNp63α. ΔNp63α expression increased EGFR mRNA, total EGFR protein, and phospho-EGFR(Y1086), whereas silencing endogenous ΔNp63 in HCC1806 cells reduced both total and phospho-EGFR levels and inhibited the ability of EGF to activate EGFR. EGFR pathway gene expression analysis indicated that ΔNp63 alters EGFR-regulated genes involved in cell adhesion, migration, and angiogenesis. Addition of EGF or neutralizing EGFR antibodies demonstrated that EGFR activation is responsible for ΔNp63-mediated loss of cellular adhesion. Finally, immunohistochemical staining showed that p63-positive triple-negative breast cancers were more likely to express high levels of EGFR than p63-negative cancers, corroborated by in silico analysis of gene expression profiling data. CONCLUSIONS: These data identify EGFR as a major target for ΔNp63 regulation that influences cancer cell adhesion in basal-like triple-negative breast cancer.
650    _2
$a buněčná adheze $x genetika $7 D002448
650    _2
$a nádorové buněčné linie $7 D045744
650    _2
$a proliferace buněk $x genetika $7 D049109
650    _2
$a epidermální růstový faktor $x genetika $x metabolismus $7 D004815
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a regulace genové exprese u nádorů $7 D015972
650    _2
$a lidé $7 D006801
650    _2
$a membránové proteiny $x genetika $7 D008565
650    _2
$a invazivní růst nádoru $x genetika $7 D009361
650    _2
$a metastázy nádorů $7 D009362
650    _2
$a proteomika $7 D040901
650    _2
$a erbB receptory $x genetika $7 D066246
650    _2
$a signální transdukce $7 D015398
650    _2
$a triple-negativní karcinom prsu $x farmakoterapie $x genetika $x patologie $7 D064726
655    _2
$a časopisecké články $7 D016428
700    1_
$a Nekulova, Marta $u RECAMO, Masaryk Memorial Cancer Centre, Zluty kopec 7, 65633, Brno, Czech Republic.
700    1_
$a Orzol, Paulina $u RECAMO, Masaryk Memorial Cancer Centre, Zluty kopec 7, 65633, Brno, Czech Republic.
700    1_
$a Nenutil, Rudolf $u RECAMO, Masaryk Memorial Cancer Centre, Zluty kopec 7, 65633, Brno, Czech Republic.
700    1_
$a Podhorec, Jan $u Clinic of Comprehensive Cancer Care, Zluty kopec 7, 65633, Brno, Czech Republic.
700    1_
$a Svoboda, Marek $u Clinic of Comprehensive Cancer Care, Zluty kopec 7, 65633, Brno, Czech Republic.
700    1_
$a Dvorakova, Petra $u RECAMO, Masaryk Memorial Cancer Centre, Zluty kopec 7, 65633, Brno, Czech Republic.
700    1_
$a Pjechova, Mariana $u RECAMO, Masaryk Memorial Cancer Centre, Zluty kopec 7, 65633, Brno, Czech Republic.
700    1_
$a Hernychova, Lenka $u RECAMO, Masaryk Memorial Cancer Centre, Zluty kopec 7, 65633, Brno, Czech Republic.
700    1_
$a Vojtesek, Borivoj $u RECAMO, Masaryk Memorial Cancer Centre, Zluty kopec 7, 65633, Brno, Czech Republic. vojtesek@mou.cz.
700    1_
$a Coates, Philip J $u RECAMO, Masaryk Memorial Cancer Centre, Zluty kopec 7, 65633, Brno, Czech Republic. philip.coates@mou.cz.
773    0_
$w MED00009361 $t Breast cancer research and treatment $x 1573-7217 $g Roč. 163, č. 3 (2017), s. 475-484
856    41
$u https://pubmed.ncbi.nlm.nih.gov/28349272 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20180404 $b ABA008
991    __
$a 20180419102253 $b ABA008
999    __
$a ok $b bmc $g 1288204 $s 1007531
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2017 $b 163 $c 3 $d 475-484 $e 20170327 $i 1573-7217 $m Breast cancer research and treatment $n Breast Cancer Res Treat $x MED00009361
LZP    __
$a Pubmed-20180404

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...